Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens.
Neutralising antibody responses to six post-exposure regimens of human diploid cell strain rabies vaccine with or without human rabies immune globulin (HRIG) were studied in 98 patients. The total amount of vaccine used was 22-34% of that required by conventional regimens. Vaccine was given at multiple sites intradermally or subcutaneously with or without adjuvant. Antibody was detectable within 7 days of the first dose in all subjects only in the groups given 0.1 ml intradermally at 8 sites. From day 14 onwards all groups showed an excellent antibody response; there was little difference between the various regimens. Suppression of the response to 8-site intradermal vaccination by a large dose of HRIG could be prevented by giving the second dose of vaccine on day 7 rather than day 14.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007271:Injections, Intradermal / Q000379:methods; D007279:Injections, Subcutaneous / Q000379:methods; D008297:Male; D008875:Middle Aged; D011818:Rabies / Q000517:prevention & control; D011819:Rabies Vaccines / Q000008:administration & dosage*; D013997:Time Factors; D014611:Vaccination / Q000191:economics
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D011819:Rabies Vaccines